Lv31
300 积分 2023-07-21 加入
中国宫颈癌规范诊疗质量控制指标(2022版)
4小时前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
28天前
已完结
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
30天前
已关闭
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
30天前
已关闭
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
1个月前
已完结
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
1个月前
已完结
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
1个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
1个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
1个月前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
2个月前
已完结
皖公网安备34019202002308
